<DOC>
	<DOCNO>NCT00109252</DOCNO>
	<brief_summary>This open-label , multicenter study design evaluate efficacy safety efalizumab administer weekly SC ( subcutaneous ) dose 1.0 mg/kg follow efalizumab taper subject plaque psoriasis previously participate Study ACD2390g .</brief_summary>
	<brief_title>A Study Evaluate Raptiva Adults With Plaque Psoriasis Previously Enrolled Study ACD2390g</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Previous participation Study ACD2390g For woman childbearing potential , continue use acceptable method contraception duration participation study Willingness continue hold sun exposure reasonably constant avoid use tan booth UV light source throughout study Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure efalizumab Systemic therapy psoriasis ( ET Day 0 FU Day 84 upon relapse unusual presentation psoriasis FU period , whichever occur first ) Systemic immunosuppressive drug indication ( ET Day 0 FU Day 84 ) Topical therapy psoriasis ( ET Day 0 ET Day 84 ) Live virus bacteria vaccine ( ET Day 0 FU Day 84 ) Other vaccine allergy desensitization ( recommend schedule FU Day 84 ) Other experimental drug treatment ( ET Day 0 FU Day 84 ) BetaBlockers , ACE inhibitor , interferon , quinidine , antimalarial drug , lithium ( clinically indicate , medication allow dosage hold constant ET Day 0 TT Day 84 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>